🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to researchers.

A Global Health Concern

Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million instances per year. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options currently available.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in concurrent days. This drug, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This milestone represents a major breakthrough in the management of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Research Study Outcomes and Worldwide Availability

According to findings published in a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which involves a dual-drug approach. The study involved nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced optimism. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for gonorrhoea control. This is viewed as essential to reduce the burden of the infection for individuals and to halt the transmission of untreatable gonorrhoea worldwide.